CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-12-21 DOI:10.1080/2162402x.2023.2294563

Coralie Schoumacher, Valentin Derangère, Gwladys Gaudillière-Le Dain, Titouan Huppe, David Rageot, Alis Ilie, Angélique Vienot, Christophe Borg, Franck Monnien, Frederic Bibeau, Caroline Truntzer, François Ghiringhelli, For the CGE-Pancreas investigators

引用次数: 0

Abstract

Stratification of the prognosis of pancreatic cancer (PDAC) patients treated by surgery is based solely on clinical variables, such as tumor stage and node status. The development of biomarkers of ...

查看原文本刊更多论文

与临床评分相关的 CD3-CD8 免疫评分可对 PDAC 的预后进行分层，与辅助化疗或新辅助化疗无关

对接受手术治疗的胰腺癌（PDAC）患者的预后进行分层完全基于临床变量，如肿瘤分期和结节状态。胰腺癌生物标志物的开发 ...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.